Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm , a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar(R) (triptorelin) in Canada. Knight expects to take over commercial activities from Debiopharm's current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar(R) was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.

MONTREAL and LAUSANNE, Switzerland , Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex- USA ) specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada . Knight expects to take over commercial activities from Debiopharm's current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 4:30 PM PST at the Westin St. Francis Hotel in San Francisco. A copy of the presentation will be available at www.gud-knight.com.